Home | Business News | Browse by Publication | B | Business Wire

Taro Pharmaceuticals Receives UK Approval for Warfarin Tablets.

Publication: Business Wire
Publication Date: 08-JAN-02
Format: Online
Delivery: Immediate Online Access

Article Excerpt
Business Editors and Medical/Health Writers

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Jan. 8, 2002

Taro Pharmaceutical Industries Ltd. (NASDAQ/NMS: TARO) reported today that its UK subsidiary, Taro Pharmaceuticals (UK) Ltd., has received approval from the United Kingdom Medicines Control Agency for Taro's Marketing Authorization Applications for Warfarin Tablets.

The approvals cover Warfarin Tablets in all four strengths currently in use in the UK, 0.5 mg, 1 mg, 3 mg, and 5 mg. Taro's Warfarin Tablets are...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!



More articles from Business Wire
UniFirst Declares Regular Cash Dividends., January 08, 2002
Axcelis Names Jan Paul van Maaren Vice President and General Manager o..., January 08, 2002
Mobilocity to Host Executive Education Seminar on Mobile Technology., January 08, 2002
Mid-America Announces Common Dividend., January 08, 2002
Talk Visual Develops Reseller and Dealer Channels., January 08, 2002

Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.